Direct costs for the treatment of inflammatory bowel diseases

Česká verzia

Authors: Zelinková Z. ¹; Podmanický D. ^2,3; Kadlečková B. ¹
Authors place of work: Gastroenterologické oddelenie a oddelenie digestívnej endoskopie, Interná Klinika SZU, Univerzitná Nemocnica – Nemocnica sv. Michala, Bratislava ¹; Chirurgické oddelenie, Univerzitná Nemocnica – Nemocnica sv. Michala, Bratislava ²; LF SZÚ, Bratislava ³
Published in the journal: Gastroent Hepatol 2020; 74(1): 35-38
Category: IBD: Review Article

Summary

The direct cost of treating non-specific inflammatory bowel dis eases (IBD) is an economicaly significant social burden. They include the cost of outpatient and hospital care, the cost of medicines and dia gnostic procedures, and the share of these costs in the over all burden varies from country to country. It is therefore neces sary to know the specific situation in the country in order to develop a cost reduction strategy. The present article reviews recent studies to as sess the cost of IBD treatment in different countries and proposes possible measures to reduce these costs.

Confl ct of Interest: The authors declare that the article/manuscript complies with ethical standards, patient anonymity has been respected, and they state that they have no financial, advisory or other commercial interests in relation to the subject matter.

Publication Ethics: This article/manuscript has not been published or is currently being submitted for another review. The authors agree to publish their name and e-mail in the published article/manuscript.

Dedication: The article/manuscript is not supported by a grant nor has it been created with the support of any company.

The Editorial Board declares that the manuscript met the ICMJE „uniform requirements“ for biomedical papers.

Keywords:

inflam matory bowel dis ease – direct cost – Health care

Zdroje

1. Peyrin-Biroulet L, Sandborn W, Sands BE et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol 2015; 110 (9): 1324–1338. doi: 10.1038/ajg.2015.233.

2. Maaser C, Sturm A, Vavricka SR et al. ECCO-ESGAR guideline for diagnostic assessment in IBD. Part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis 2018; 13 (2): 144–164. doi: 10.1093/ecco-jcc/jjy113.

3. Jussila A, Virta LJ, Pukkala E et al. Mortality and causes of death in patients with inflammatory bowel disease: a nationwide register study in Finland. J Crohns Colitis 2014; 8 (9): 1088–1096. doi: 10.1016/j.crohns.2014.02.015.

4. Alatab S, Sepanlou SG, Ikuta K et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol 2020; 5 (1): 17–30. doi: 10.1016/S2468-1253 (19) 30333-4.

5. Dearthealth. [online]. Available from: www.dearhealth.com.

6. Olén O, Askling J, Sachs MC et al. Mortality in adult-onset and elderly-onset IBD: a nationwide register-based cohort study 1964–2014. Gut 2020; 69 (3): 453–461. doi: 10.1136/gutjnl-2018-317572.

7. Lichtenstein GR, Shahabi A, Seabury SA et al. Lifetime economic burden of Crohn’s disease and ulcerative colitis by age at diagnosis. Clin Gastroenterol Hepatol 2019. In press. doi: 10.1016/j.cgh.2019.07.022.

8. Pillai N, Dusheiko M, Maillard MH et al. The evolution of health care utilisation and costs for inflammatory bowel disease over ten years. J Crohns Colitis 2019; 13 (6): 744–754. doi: 10.1093/ecco-jcc/jjz003.

9. Kuenzig ME, Benchimol EI, Lee L et al. The impact of inflammatory bowel disease in canada 2018: direct costs and health services utilization. J Can Assoc Gastroenterol 2019; 2 (Suppl 1): S17–S33. doi: 10.1093/jcag/gwy055.

10. Lo B, Vind I, Vester-Andersen MK et al. Direct and indirect costs of inflammatory bowel disease: ten years of follow-up in a danish population-based inception cohort. J Crohns Colitis 2020; 14 (1): 53–63. doi: 10.1093/ecco-jcc/ jjz096.

11. Ng SC, Shi HY, Hamidi N et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21^st century: a systematic review of population-based studies. Lancet 2018; 390 (10114): 2769–2778. doi: 10.1016/S0140-6736 (17) 32448-0.

12. Suchá V, Kadlečková B, Repáková B et al. Nedostatočná liečba tiopurínmi u pacientov s nešpecifickými zápalovými ochoreniami čreva odoslaných na anti TNF liečbu. Gastroent Hepatol 2016; 70 (4): 335–339. doi: 10.14735/amgh2016335.

13. de Boer NK, Peyrin-Biroulet L, Jharap B et al. Thiopurines in inflammatory bowel disease: new findings and perspectives. J Crohns Colitis 2018; 12 (5): 610–620. doi: 10.1093/ecco-jcc/jjx181.

14. Schnitzler F, Fidder H, Ferrante M et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort. Gut 2009; 58 (4): 492–500. doi: 10.1136/gut.2008.155812.

15. Atreya R, Neurath MF. Mechanisms of molecular resistance and predictors of response to biological therapy in inflammatory bowel disease. Lancet Gastroenterol Hepatol 2018; 3 (11): 790–802. doi: 10.1016/S2468-1253 (18) 30265-6.

16. de Groof EJ, Stevens TW, Eshuis EJ et al. Cost-effectiveness of laparoscopic ileocaecal resection versus infliximab treatment of terminal ileitis in Crohn’s disease: the LIR!C trial. Gut 2019; 68 (10): 1774–1780. doi: 10.1136/ gutjnl-2018-317539.

17. Ponsioen CY, de Groof EJ, Eshuis EJ et al. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn’s disease: a randomised controlled, open-label, multicentre trial. Lancet Gastroenterol Hepatol 2017; 2 (11): 785–792. doi: 10.1016/S2468-1253 (17) 30248-0.

18. Kucharzik T, Wittig BM, Helwig U et al. Use of intestinal ultrasound to monitor Crohn’s disease activity. Clin Gastroenterol Hepatol 2017; 15 (4): 535–542. doi: 10.1016/j.cgh.2016.10.040.

19. Taylor SA, Mallett S, Bhatnagar G et al. Diagnostic accuracy of magnetic resonance enterography and small bowel ultrasound for the extent and activity of newly diagnosed and relapsed Crohn’s disease (METRIC): a multicentre trial. Lancet Gastroenterol Hepatol 2018; 3 (8): 548–558. doi: 10.1016/S2468-1253 (18) 30161-4.

20. Bryant RV, Friedman AB, Wright EK et al. Gastrointestinal ultrasound in inflammatory bowel disease: an underused resource with potential paradigm-changing application. Gut 2018; 67 (5): 973–985. doi: 10.1136/gutjnl-2017-315655.

21. de Jong MJ, van der Meulen-de Jong AE, Romberg-Camps MJ et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet 2017; 390 (10098): 959–968. doi: 10.1016/S0140-6736 (17) 31 327-2.